-- シュプリーム・ペトロケム（NSE:SPLPETRO、BOM:500405）は、マハラシュトラ州ナゴタンにあるアムドシ工場でEPS（発泡ポリスチレン）第2期拡張工事を稼働させ、年間生産能力を3万トン増強したと、火曜日にインド証券取引所に提出した書類で明らかにした。 同社の株価は水曜日の取引で1%以上上昇した。 提出書類によると、今回の拡張により、同社のEPS生産能力は年間8万5000トンから11万5000トンに増加した。 また、このプロジェクトには約5億4000万インドルピーの投資が行われ、内部留保資金で賄われたという。 同社は、今回の生産能力増強は包装、建設、コールドチェーン分野からの需要に対応することを目的としていると述べた。
Related Articles
Asia
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
$ASX:NAB
Asia
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
$ASX:CUV
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF